A Big Bounce for Cypress Bioscience
Shares in Forest Laboratories (FRX) and Cypress Bioscience (CYPB) climbed May 23 after a neurological drug they are co-developing, Milnacipran, showed positive results in a late-stage clinical trial.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Turns Out It Will Be Congress's Fault When Stocks Crash
- Facebook and Google Helped Anti-Refugee Campaign in Swing States
- Ford to Take $267 Million Hit From Recall of F-Series Trucks